Status:
COMPLETED
The Effect of Glucagon Like Peptide (GLP)-1 in Psoriasis
Lead Sponsor:
Annesofie Faurschou
Collaborating Sponsors:
University of Copenhagen
Conditions:
Psoriasis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The objective of this study is to investigate the effect of the GLP-1 analogue Victoza® on psoriasis in a double-blinded, randomized placebo-controlled clinical trial.
Eligibility Criteria
Inclusion
- Caucasians above 18 years of age
- Plaque psoriasis
- PASI score \>10
- No treatment or stable treatment of psoriasis during at least 3 months before inclusion
- Steady weight through 3 months with a body mass index (BMI) above 27 kg/m2
- Normal blood pressure
- Spiral or hormonal birth control for fertile women during the entire treatment period and at least 3 days after the end of the treatment period (\~5 times the plasma half-life)
Exclusion
- Psoriasis arthritis
- Fasting plasma glucose \> 7.5 mmol/L or HbA1c \> 7.5%
- Type 1 diabetes
- Treatment for type 2 diabetes with GLP-1-based medicine (DDP-4-inhibitors or GLP-1-receptor-agonists)
- Heart failure, NYHA class III-IV
- Uraemia, end-stage renal disease, or any other cause of impaired renal function with s-creatinine \>150 µM and/or albuminuria
- Liver disease (alanine amino transferase (ALAT) and/or aspartate amino transferase (ASAT) \>2 x upper normal serum levels)
- Anaemia
- Acute or chronic pancreatitis
- Struma or thyroid cancer
- Pregnancy or breast feeding
- Inability to complete the study
Key Trial Info
Start Date :
October 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2013
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT01460069
Start Date
October 1 2011
End Date
May 1 2013
Last Update
June 21 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Gentofte Hospital
Hellerup, Denmark, 2900